Sunday, January 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Top Pharma and Research Institutes Partner for ‘TB Drug Accelerator’

by Global Biodefense Staff
June 27, 2012

A groundbreaking collaborative between drug makers and research institutions seeks to leverage collective abilities to speed up the discovery of essential new treatments for tuberculosis (TB).

The partnership, known as the TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research. Participating pharmaceutical companies will open up targeted sections of their compound libraries and share data with each other and several research institutions. Together they will work to develop the best prospects, regardless of where the drug originated.  The TBDA is composed of the following organizations:

  • Bill & Melinda Gates Foundation
  • Infectious Disease Research Institute
  • National Institute of Allergy and Infectious Diseases
  • Texas A&M University
  • Weill Cornell Medical College
  • Abbott
  • AstraZeneca
  • Bayer Healthcare AG
  • Eli Lilly
  • GlaxoSmithKline
  • Merck & Co.
  • Sanofi

The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month.  Existing drugs are all at least 50 years old and require six months to cure the disease. The lengthy process contributes to 20-30% of patients dropping out before completion. Such high default rates lead to increased mortality, contribute to TB drug resistance and allow patients to continue to infect others.

Tuberculosis is a bacterial infection that attacks the respiratory system and other organs. It is the second leading infectious cause of death worldwide, having killed nearly 1.4 million people in 2010 alone. At any given moment, more than 12 million people around the world are suffering from active TB.  Shortening treatment regimens to even two months would keep an additional one million people on treatment each year.

“TB drug discovery has reached a crossroads,” said Dr. Carl Nathan, Professor and Chairman of the Department of Microbiology and Immunology at Weill Cornell Medical College. “Finding new and faster-acting TB drugs will take a new kind of partnership, connecting not only academia and industry, but drug company with drug company. The TB Drug Accelerator is a historic experiment in innovative collaboration.”

Aided by nearly $20 million from the Gates Foundation, partners officially launched the TBDA in April and have begun the first round of screening for new TB drug candidates. The TBDA aims to develop five new preclinical drug candidates with treatment-shortening potential within 5 years and proof-of-concept for a one-month three-drug regimen within 10 years.

Resources:
Critical Pathways to TB Drug Regimens (CPTR)
Global Alliance for TB Drug Development
Gates Foundation Tuberculosis Strategy Overview (.pdf)
 
Tags: Tuberculosis

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC